Skip to content

The Natural History of Mucolipidosis Type IV

The Natural History of Mucolipidosis Type IV

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01067742
Enrollment
7
Registered
2010-02-12
Start date
2009-02-19
Completion date
2021-07-07
Last updated
2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucolipidosis Type IV

Keywords

Mucolipidosis, retinal dystrophy, mucolipin-1,, lysosomal storage disease, gastrin, mental retardation,, dysmyelination, dysplastic corpus callosum,corneal clouding

Brief summary

The purpose of this study is to define the natural history of Mucolipidosis Type IV and identify potential clinical outcome measures.

Detailed description

Mucolipidosis type IV (MLIV) is an autosomal recessive disorder typically characterized by severe psychomotor delay evident by the end of the first year of life and slowly progressive visual impairment during the first decade as a result of a combination of corneal clouding and retinal degeneration. By the end of the first decade of life, and always by their early teens, individuals with typical MLIV develop severe visual impairment as a result of retinal degeneration. MLIV is an under-diagnosed and unique lysosomal disorder in that it often is mistaken either for cerebral palsy or for a retinal dystrophy of unknown cause. In addition, it is caused by a defect in a cation channel rather than by a lysosomal hydrolase. This study represents the only prospective clinical study in this patient population. Now that an animal model has been created and novel therapies will likely be tested, it is particularly important to define the natural history of this disorder and identify potential clinical outcome measures.

Interventions

None listed

Sponsors

Baylor Research Institute
Lead SponsorOTHER
Rare Diseases Clinical Research Network
CollaboratorNETWORK
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

Subjects must: * Have a definitive diagnosis of MLIV based at least on a compatible history and significantly elevated blood gastrin levels * Be able to travel to the Baylor Institute of Metabolic Disease in Dallas and spend 2-3 working days on site * Be able to tolerate a general exam and neurological exam * Be able to tolerate a modest amount of blood drawing, provide a urine specimen, and have a skin biopsy(if not previously done) * Be able to tolerate the performance of necessary neuroimaging studies to include EEG and Head MRI * Be able to tolerate a neuropsychological testing and rehabilitation evaluation

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Neuropsychological testingAnnual by 5 years

Secondary

MeasureTime frame
Blood testsAnnual by 5 years
Urine testsAnnual by 5 years
MRI of the brainAnnual by 5 years
Rehabilitation evaluationAnnual by 5 years
Nutritional status evaluationAnnual by 5 years
Skin biopsy1 year only

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026